SFPI-FPIM

Tangent Works is a data science startup specializing in real-time predictive analytics. The company has developed a platform that automates the repetitive and manual tasks traditionally associated with data science, particularly in model building. By leveraging advancements in machine learning, Tangent Works bridges the gap between academic research and practical industry applications. Its technology uncovers hidden dynamics within data, enabling businesses to generate accurate predictive models for time series analysis. This innovative approach allows machine learning services to be executed directly on devices, enhancing operational efficiency and decision-making for organizations.

Cohabs is a provider of rental co-living spaces that offers fully furnished shared homes for nomads worldwide. The company focuses on creating a network of sustainable and community-oriented residences that cater to the needs of its members. Cohabs enhances the living experience by providing amenities such as weekly cleaning, shared groceries, and monthly breakfasts. In addition, the company fosters a vibrant community through organized events, dinners, and social gatherings, promoting interaction among residents. By prioritizing flexibility and a tech-driven approach, Cohabs aims to create an enriching environment for individuals seeking adaptable living arrangements.

Axelera AI specializes in developing hardware and software platforms designed to accelerate artificial intelligence tasks, particularly for edge computing. Its flagship product, the Metis™ AI Platform, integrates both hardware and software components to deliver high-performance, energy-efficient AI inference solutions. The company is headquartered in Eindhoven with R&D offices in Belgium, Switzerland, and Italy.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

Magnax is a company that specializes in yokeless axial flux technology, which is used to create high power density motors for electric powertrains and aerospace propulsion systems. Their innovative motors are designed with a patented cooling system that maintains low stator temperatures, enhancing robustness and efficiency. This technology reduces core losses through the use of oriented electrical steel, allowing manufacturers in the e-mobility sector to develop lighter and more energy-efficient vehicles. Magnax operates through strategic subsidiaries, such as Traxial, which focuses on ground-based e-mobility applications, and Axyal, which targets the aerospace market, each requiring tailored approaches to effectively serve their respective industries.

EyeD Pharma SA is a pharmaceutical company based in Liège, Belgium, specializing in the development and commercialization of innovative drug products for ophthalmology. The company focuses primarily on the treatment of glaucoma, a condition historically managed with daily eye drops. EyeD Pharma aims to enhance the quality of life for patients by reducing the side effects associated with traditional therapies. In collaboration with ophthalmologists, the company offers new treatment options and surgical products that improve clinical practices and provide therapeutic assistance that is currently lacking in the market. Through its efforts, EyeD Pharma seeks to advance the standard of care in ophthalmology.

PDC*line Pharma is a French-Belgium clinical-stage biotech company developing active immunotherapies for cancer using its proprietary Plasmacytoid Dendritic Cell line, PDC*line. These therapies aim to stimulate potent and scalable antitumor immune responses.

Qpinch is a company focused on transforming wasted industrial heat into valuable process heat, thereby generating carbon-neutral steam and reducing energy costs for various industries. By utilizing an innovative chemical heat transformer, Qpinch helps businesses optimize their existing industrial assets, leading to immediate energy savings while minimizing their environmental impact. The company's technology allows clients to effectively repurpose waste heat, contributing to a more sustainable energy landscape and enhancing operational efficiency.

Itsme is a secure mobile application that enables users to verify their personal identity and approve transactions safely and conveniently on their phones. It facilitates digital interactions by allowing users to log in securely, share data, and confirm orders while maintaining privacy.

Imcyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, specializing in innovative immunotherapeutic solutions aimed at treating severe chronic autoimmune diseases. Founded in 2010, Imcyse is pioneering a unique technology platform that employs Imotopes™, specifically modified peptides that target immune cells responsible for organ damage. This approach facilitates the generation of cytolytic CD4 T-cells, which selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, thereby addressing diseases with limited treatment options. The company has shown proof of concept across various indications and has completed its initial clinical trial for type 1 diabetes, yielding promising outcomes. In addition to type 1 diabetes, Imcyse is actively developing a pipeline of therapies for multiple autoimmune diseases, aiming to provide effective treatment while preserving overall immune defense.

Endo Tools Therapeutics is a medical device company focused on gastroenterology, developing and manufacturing therapeutic devices and the ENDOMINA open platform that supports therapeutic endoscopic procedures. Founded in 2008 and based in Belgium, the company develops catheters with therapeutic channels and increased degrees of freedom for interventional gastro-enterology, as well as tools for endoscopic suturing and tissue apposition. Its devices aim to treat obesity, digestive tract tumors, and diabetes by enabling minimally invasive surgical endoscopy.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

Miracor Medical develops cardiovascular medical devices, notably the PiCSO impulse system, a pressure‑controlled intermittent coronary sinus occlusion device designed to improve microvascular perfusion and cardiac function after acute myocardial infarction. The system supports treatment of myocardial infarction and can be used in surgical settings such as coronary artery bypass grafting to facilitate perfusion improvements. Founded in 2008, the company is based in Awans, Belgium, with a presence in Vienna, Austria.

ExeVir Bio BV is a Belgian biotechnology company founded in 2020 and headquartered in Zwijnaarde. The company specializes in developing single-domain antibody-based therapies aimed at preventing viral infections. Utilizing a llama-derived antibody technology platform, ExeVir Bio focuses on creating robust antiviral treatments, particularly targeting coronaviruses. One of its key products, VHH72-FC, binds to a conserved region of the SARS-CoV-2 spike protein, which is crucial for the virus's entry into human cells. The company has established a rapid response platform for antivirals, allowing for a quick adaptation to emerging health threats through a streamlined process for generating drug candidates. Their protein-based therapeutics are designed to be stable, cost-effective, and accessible on a global scale, addressing significant public health challenges posed by viral infections.

iTeos Therapeutics is a biotechnology company focused on immuno-oncology, developing cancer therapies that target the tumor microenvironment to overcome immune suppression and enhance efficacy of existing treatments. The company pursues small molecule and antibody approaches, including EOS-850, a small molecule antagonist of the adenosine A2A receptor, and EOS-448, an antagonist of TIGIT, with early-stage clinical programs designed to restore immune activity against tumors. By modulating metabolic and immune pathways within the tumor microenvironment, iTeos aims to improve responses across cancer types and complement immune checkpoint therapies.

Founded by experts in DNA sequencing and diagnostic analyses in oncology, OncoDNA offers precision medicine solutions for cancer treatment. It provides clinical guidance for late-stage patients, supports research, and aids drug development.

iSTAR Medical specializes in developing ophthalmic implants made from biomaterials. Its flagship product is the STARflo glaucoma implant, a non-degradable, precision-pore device designed to reduce intraocular pressure in open angle glaucoma patients by enhancing natural fluid outflow. The company's products are sold through distributors worldwide and it operates from its eco-friendly R&D and manufacturing facility near Namur, Belgium.

Ninepointfive is a venture capital investment firm based in Antwerp, Belgium, founded in 2019. It co-invests with corporate partners to support tech startups from pre-seed to maturity, combining venture capital with corporate acceleration to drive growth. The firm works with brands such as Beiersdorf, Telenet, and Agfa to provide strategic value, resources, and market access for portfolio companies. Ninepointfive focuses on sectors including energy, information technology, B2B software as a service, and materials and resources, seeking startups with scalable technology and practical applications. By leveraging corporate networks and investment expertise, it helps founders move from early validation to scale in a pragmatic, value-driven approach.

Unifly is a developer of unmanned traffic management software focused on the secure integration of drones into global airspace. Founded in 2015 by aerospace experts, the company emerged from a vision shared by air traffic controllers who recognized the need for effective management of the increasing number of drones. Unifly's award-winning platform connects authorities and drone operators, allowing for real-time monitoring and management of drone traffic, while providing pilots with essential information regarding the legal status of their flights. The platform is already utilized by national authorities in Germany, Denmark, Austria, and Belgium, and Unifly is also active in the United States and several projects worldwide, including Africa and Asia. By fostering collaboration with various stakeholders, Unifly aims to enhance airspace safety and facilitate the seamless integration of drones into everyday life, addressing critical concerns regarding safety and oversight in both recreational and commercial drone activities.

Imcyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, specializing in innovative immunotherapeutic solutions aimed at treating severe chronic autoimmune diseases. Founded in 2010, Imcyse is pioneering a unique technology platform that employs Imotopes™, specifically modified peptides that target immune cells responsible for organ damage. This approach facilitates the generation of cytolytic CD4 T-cells, which selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, thereby addressing diseases with limited treatment options. The company has shown proof of concept across various indications and has completed its initial clinical trial for type 1 diabetes, yielding promising outcomes. In addition to type 1 diabetes, Imcyse is actively developing a pipeline of therapies for multiple autoimmune diseases, aiming to provide effective treatment while preserving overall immune defense.

Endo Tools Therapeutics is a medical device company focused on gastroenterology, developing and manufacturing therapeutic devices and the ENDOMINA open platform that supports therapeutic endoscopic procedures. Founded in 2008 and based in Belgium, the company develops catheters with therapeutic channels and increased degrees of freedom for interventional gastro-enterology, as well as tools for endoscopic suturing and tissue apposition. Its devices aim to treat obesity, digestive tract tumors, and diabetes by enabling minimally invasive surgical endoscopy.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Miracor Medical develops cardiovascular medical devices, notably the PiCSO impulse system, a pressure‑controlled intermittent coronary sinus occlusion device designed to improve microvascular perfusion and cardiac function after acute myocardial infarction. The system supports treatment of myocardial infarction and can be used in surgical settings such as coronary artery bypass grafting to facilitate perfusion improvements. Founded in 2008, the company is based in Awans, Belgium, with a presence in Vienna, Austria.

iTeos Therapeutics is a biotechnology company focused on immuno-oncology, developing cancer therapies that target the tumor microenvironment to overcome immune suppression and enhance efficacy of existing treatments. The company pursues small molecule and antibody approaches, including EOS-850, a small molecule antagonist of the adenosine A2A receptor, and EOS-448, an antagonist of TIGIT, with early-stage clinical programs designed to restore immune activity against tumors. By modulating metabolic and immune pathways within the tumor microenvironment, iTeos aims to improve responses across cancer types and complement immune checkpoint therapies.

Air Belgium S.A., established in 1979 and headquartered in Mont-Saint-Guibert, Belgium, specializes in passenger air transportation with a focus on intercontinental flights between Belgium and select destinations in Asia, including Hong Kong. The airline operates a diverse fleet equipped with economy, premium, and business class seating, catering to various passenger needs. In addition to providing comfortable in-flight experiences, Air Belgium also accommodates travelers with pets and children, and offers onboard catering services. The company is committed to delivering quality air travel at competitive prices, ensuring an enjoyable journey for its customers.

Synergia Medical is a Belgium-based medical device company developing neurostimulation technologies. It advances an optoelectronic neurostimulator platform that integrates biomaterials, optical components, biosensors and microelectronics to enable implantable and potentially MRI-safe devices. The focus is on MRI-safe, implanted neurostimulators for drug-resistant epilepsy and other indications, with wires replaced by fiber optics and photovoltaic cells that convert light into electrical impulses. Founded in 2013 and headquartered in Mont-Saint-Guibert, the company pursues next-generation neurostimulation solutions, including its NAOS platform, and has pursued ISO13485 certification. Development is supported by private investors and public research grants, reflecting a multidisciplinary approach to bring novel neurostimulation devices to market.

PharmaFluidics is a Brussels-based spin-off from the Vrije Universiteit Brussel, focusing on developing and manufacturing micro-chip based chromatography columns for use in biomarker, diagnostics, and drug research applications. The company leverages its expertise in chemical engineering and micro-fabrication technology to create high-quality solutions tailored for mixing, separation, and reaction processes at milli- to nano-scales. Their products enable researchers to identify active compounds in complex biological samples more efficiently and sensitively.

Miracor Medical develops cardiovascular medical devices, notably the PiCSO impulse system, a pressure‑controlled intermittent coronary sinus occlusion device designed to improve microvascular perfusion and cardiac function after acute myocardial infarction. The system supports treatment of myocardial infarction and can be used in surgical settings such as coronary artery bypass grafting to facilitate perfusion improvements. Founded in 2008, the company is based in Awans, Belgium, with a presence in Vienna, Austria.

Ncardia develops predictive human cellular assay systems based on human induced pluripotent stem cells (hiPSCs) to support safety and efficacy testing of drug candidates and enhance cardiovascular and neural drug screening. By producing hiPSC-derived models that reflect human disease biology, the company helps researchers and drug developers better predict human responses, streamline preclinical evaluation, and accelerate the discovery and development of new therapies.

Ncardia develops predictive human cellular assay systems based on human induced pluripotent stem cells (hiPSCs) to support safety and efficacy testing of drug candidates and enhance cardiovascular and neural drug screening. By producing hiPSC-derived models that reflect human disease biology, the company helps researchers and drug developers better predict human responses, streamline preclinical evaluation, and accelerate the discovery and development of new therapies.

PDC*line Pharma is a French-Belgium clinical-stage biotech company developing active immunotherapies for cancer using its proprietary Plasmacytoid Dendritic Cell line, PDC*line. These therapies aim to stimulate potent and scalable antitumor immune responses.

iSTAR Medical specializes in developing ophthalmic implants made from biomaterials. Its flagship product is the STARflo glaucoma implant, a non-degradable, precision-pore device designed to reduce intraocular pressure in open angle glaucoma patients by enhancing natural fluid outflow. The company's products are sold through distributors worldwide and it operates from its eco-friendly R&D and manufacturing facility near Namur, Belgium.

NovoPolymers NV is a company focused on creating sustainable solutions tailored for the photovoltaic market. It specializes in the development and production of front and back encapsulants that protect solar cells. These encapsulants are designed to enhance the power output of both crystalline silicon and thin-film solar modules, thereby adding value across the photovoltaic supply chain. Through its innovative products, NovoPolymers aims to contribute to the advancement of renewable energy technologies.

Promethera Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver diseases. Founded in 2009 and based in Mont-Saint-Guibert, Belgium, with an office in Tokyo, Japan, the company specializes in cell therapy products, notably HepaStem and H2Stem, which utilize allogeneic progenitor cells derived from healthy human adult livers. Promethera is actively working on treatments for a range of conditions, including acute-on-chronic liver failure, hemophilia, liver fibrosis, non-alcoholic steatohepatitis, liver-based metabolic diseases, and urea cycle disorders. The company also engages in strategic alliances to further its research and development efforts, enhancing its capacity to discover and commercialize effective cell therapies for liver-related ailments.

IBA engages in the distribution of crop protection and cattle feed products.

NovoPolymers NV is a company focused on creating sustainable solutions tailored for the photovoltaic market. It specializes in the development and production of front and back encapsulants that protect solar cells. These encapsulants are designed to enhance the power output of both crystalline silicon and thin-film solar modules, thereby adding value across the photovoltaic supply chain. Through its innovative products, NovoPolymers aims to contribute to the advancement of renewable energy technologies.

iTeos Therapeutics is a biotechnology company focused on immuno-oncology, developing cancer therapies that target the tumor microenvironment to overcome immune suppression and enhance efficacy of existing treatments. The company pursues small molecule and antibody approaches, including EOS-850, a small molecule antagonist of the adenosine A2A receptor, and EOS-448, an antagonist of TIGIT, with early-stage clinical programs designed to restore immune activity against tumors. By modulating metabolic and immune pathways within the tumor microenvironment, iTeos aims to improve responses across cancer types and complement immune checkpoint therapies.

NovoPolymers NV is a company focused on creating sustainable solutions tailored for the photovoltaic market. It specializes in the development and production of front and back encapsulants that protect solar cells. These encapsulants are designed to enhance the power output of both crystalline silicon and thin-film solar modules, thereby adding value across the photovoltaic supply chain. Through its innovative products, NovoPolymers aims to contribute to the advancement of renewable energy technologies.